Compounds > remogliflozin etabonate
Page last updated: 2024-12-11

remogliflozin etabonate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

remogliflozin etabonate: orally administered hypoglycemic agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9871420
CHEMBL ID2028665
CHEBI ID177541
SCHEMBL ID721678
MeSH IDM0525700

Synonyms (41)

Synonym
442201-24-3
ethyl [(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-[5-methyl-1-propan-2-yl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxyoxan-2-yl]methyl carbonate
CHEBI:177541
gsk-189075
gsk-189075a
remogliflozin etabonate
kgt-1681
remogliflozin etabonate [inn]
gsk 189075
beta-d-glucopyranoside, 5-methyl-4-((4-(1-methylethoxy)phenyl)methyl)-1-(1-methylethyl)-1h-pyrazol-3-yl, 6-(ethyl carbonate)
gsk 189075a
5-methyl-4-(4-(1-methylethoxy)benzyl)-1-(1-methylethyl)-1h-pyrazol-3-yl 6-o-(ethoxycarbonyl)-beta-d-glucopyranoside
unii-tr0qt6qsul
tr0qt6qsul ,
D10055
remogliflozin etabonate (usan/inn)
5-methyl-4-(4-(1-methylethoxy)benzyl)-1-(1-methylethyl)-1h-pyrazol-3-yl 6-o- (ethoxycarbonyl)-.beta.-d-glucopyranoside
remogliflozin etabonate [who-dd]
beta-d-glucopyranoside, 5-methyl-4-[[4-(1-methylethoxy)phenyl]methyl]-1-(1-methylethyl)-1h-pyrazol-3-yl, 6-(ethyl carbonate)
ethyl (((2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-((4-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1h-pyrazol-3-yl)oxy)tetrahydro-2h-pyran-2-yl)methyl) carbonate
5-methyl-1-(propan-2-yl)-4-((4-((propan-2-yl)oxy)phenyl)methyl)-1h-pyrazol-3-yl 6-o-(ethoxycarbonyl)-.beta.-d-glucopyranoside
remogliflozin etabonate [usan]
bhv-091009
CHEMBL2028665
gsk189075
gsk189075a
SCHEMBL721678
3-(6-o-ethoxycarbonyl-beta-d-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)methyl]-1-isopropyl-5-methylpyrazole
UAOCLDQAQNNEAX-ABMICEGHSA-N
3-(6-o-ethoxycarbonyl-beta-d-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)-methyl]-1-isopropyl-5-methylpyrazole
AKOS030528241
DB12935
bdbm50559516
HY-14945
S0993
Q7312052
CS-0003650
DTXSID50963191
MS-29684
remogliflozin etabonate (gsk189075)
BR162756

Research Excerpts

Overview

Remogliflozin etabonate is a prodrug based on benzylpyrazole glucoside. It is metabolized to its active form, remogl iflozin, in the body.

ExcerptReferenceRelevance
"Remogliflozin etabonate (RE) is a prodrug of remogliflozin, an SGLT2 inhibitor under development."( Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus.
Mikhail, N, 2015)		2.58
"Remogliflozin etabonate is a prodrug based on benzylpyrazole glucoside and is metabolized to its active form, remogliflozin, in the body."( Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.
Fujikura, H; Fujimori, Y; Isaji, M; Ishikawa-Takemura, Y; Katsuno, K; Nakashima, I, 2008)		2.51

Toxicity

ExcerptReferenceRelevance
" Concomitant administration of metformin and RE was well tolerated with minimal hypoglycemia, no serious adverse events, and no increase in lactic acid."( Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.
Dobbins, RL; Hussey, EK; James, CD; Kapur, A; O'Connor-Semmes, R; Polli, JW; Rafferty, B; Tao, W, 2013)		0.64
" Treatment-emergent adverse events (TEAEs), safety laboratory values, electrocardiogram, and vital signs were evaluated."( Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
Alva, H; Aravind, SR; Asirvatham, A; Balamurugan, R; Barkate, H; Chawla, M; Dharmalingam, M; Gaikwad, R; Goyal, R; Kadam, P; Katare, S; Kodgule, R; Mohan, B; Paramesh, S; Pendse, A; Shembalkar, J; Suryawanshi, S; Tandon, M; Thacker, H; Vaidyanathan, S, 2020)		0.87
"5%), including adverse events (AEs) of special interest (hypoglycemic events, urinary tract infection, genital fungal infection)."( Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
Alva, H; Aravind, SR; Asirvatham, A; Balamurugan, R; Barkate, H; Chawla, M; Dharmalingam, M; Gaikwad, R; Goyal, R; Kadam, P; Katare, S; Kodgule, R; Mohan, B; Paramesh, S; Pendse, A; Shembalkar, J; Suryawanshi, S; Tandon, M; Thacker, H; Vaidyanathan, S, 2020)		0.87
" There were no severe or serious adverse events (SAEs) and no increase in lactic acid concentration was reported during the study."( Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin.
Andrews, S; Cheatham, B; Dobbins, R; Hanmant, B; Hussey, EK; O'Connor-Semmes, R; Sagar, K; Tao, W; Wilkison, WO, 2021)		0.89
"Co-administration of doses of remogliflozin etabonate (500 mg BID or 750 mg BID) greater than the commercial dose (100 mg BID) with metformin (2000 mg BID) was shown to be safe and effective during the observation period."( Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin.
Andrews, S; Cheatham, B; Dobbins, R; Hanmant, B; Hussey, EK; O'Connor-Semmes, R; Sagar, K; Tao, W; Wilkison, WO, 2021)		1.18
" The study endpoints were mean changes from baseline (CFB) in HbA1c (primary), fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), body weight (BW) and blood pressure (BP) for efficacy and adverse events (AE) monitoring for safety assessments."( Efficacy and Safety of a Fixed Dose Combination of Remogliflozin Etabonate and Vildagliptin in Patients with Type-2 Diabetes Mellitus: A Randomized, Active-Controlled, Double-Blind, Phase III Study.
Barkatestrong/Strong, H; Khaladkar, K; Mohan, B; Suryawanshi, S, 2022)		0.97

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic, pharmacodynamic (urine glucose and fasting plasma glucose), and safety (adverse events, vital signs, ECG, clinical laboratory parameters including lactic acid) assessments were performed at check-in and throughout the treatment periods."( Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.
Dobbins, RL; Hussey, EK; James, CD; Kapur, A; O'Connor-Semmes, R; Polli, JW; Rafferty, B; Tao, W, 2013)		0.64
" Metformin did not affect the AUC of RE, remogliflozin, or its active metabolite, GSK279782, although Cmax values were slightly lower for remogliflozin and its metabolite after co-administration with metformin compared with administration of RE alone."( Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.
Dobbins, RL; Hussey, EK; James, CD; Kapur, A; O'Connor-Semmes, R; Polli, JW; Rafferty, B; Tao, W, 2013)		0.64
" As shown by pharmacodynamic measurements of urinary glucose excretion, there was no clinically significant reduction in the ability of remogliflozin to inhibit SGLT2."( Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment.
Cheatham, B; Dobbins, RL; Hussey, EK; Kapur, A; O'Connor-Semmes, R; Tao, W; Walker, S; Wang-Smith, L; Wilkison, WO; Ye, J, 2015)		0.66

Compound-Compound Interactions

ExcerptReferenceRelevance
" The present study (Clintrials number NCT00519480) was conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of remogliflozinetabonate, an SGLT2 inhibitor, withdoses (500 mg and 750 mg BID) greater than the commercial dose (100 mg BID)in combination with metformin with minimum daily dose of 2000 mg given in two divided doses."( Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin.
Andrews, S; Cheatham, B; Dobbins, R; Hanmant, B; Hussey, EK; O'Connor-Semmes, R; Sagar, K; Tao, W; Wilkison, WO, 2021)		0.89
" Cohort 2 subjects were administered with either remogliflozin etabonate 750 mg BID or placebo BID (2:1) in addition to metformin for 13 days."( Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin.
Andrews, S; Cheatham, B; Dobbins, R; Hanmant, B; Hussey, EK; O'Connor-Semmes, R; Sagar, K; Tao, W; Wilkison, WO, 2021)		1.14

Bioavailability

ExcerptReferenceRelevance
" Oral administration of the IR tablet of RE showed similar bioavailability of R compared with small intestine delivery with both suspension and solution."( Regional gastrointestinal delivery of remogliflozin etabonate in humans.
Dobbins, R; Doll, WJ; Hussey, EK; O'Connor-Semmes, RL; Page, RC; Sandefer, EP; Tao, W, 2013)		0.66
" Remogliflozin etabonate, a novel agent, is an orally bioavailable prodrug of remogliflozin, which is a potent and selective sodium-glucose co-transporter-2 inhibitor."( Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
Alva, H; Aravind, SR; Asirvatham, A; Balamurugan, R; Barkate, H; Chawla, M; Dharmalingam, M; Gaikwad, R; Goyal, R; Kadam, P; Katare, S; Kodgule, R; Mohan, B; Paramesh, S; Pendse, A; Shembalkar, J; Suryawanshi, S; Tandon, M; Thacker, H; Vaidyanathan, S, 2020)		1.78

Dosage Studied

ExcerptRelevanceReference
" In Part A, 10 healthy subjects participated in 5 dosing periods where they received RE (20 mg, 50 mg, 150 mg, 500 mg, or 1000 mg) or placebo (4:1 active to placebo ratio per treatment period)."( First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.
Dobbins, RL; Hompesch, M; Hussey, EK; James, CD; Kapur, A; Mikoshiba, I; Nunez, DJ; O'Connor-Semmes, R; Polli, JW; Smith, GA; Tao, W, 2013)		0.66
" We observed a statistically significant trend in the RE dose-response relationship for change from baseline in HbA1c at week 12 (p < 0."( Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes.
Almond, SR; Dobbins, R; Kemp, GL; Kler, L; O'Connor-Semmes, R; Sykes, AP; Walker, S; Wilkison, WO, 2015)		0.67
" In contrast to other SGLT2 inhibitors which accumulate in patients with renal impairment, adjustment of the dosage of RE in subjects with mild or moderate renal impairment is not indicated based on the observations in this study."( Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment.
Cheatham, B; Dobbins, RL; Hussey, EK; Kapur, A; O'Connor-Semmes, R; Tao, W; Walker, S; Wang-Smith, L; Wilkison, WO; Ye, J, 2015)		0.66
" Normalization of glycemic index can be achieved by dosing combinations of metformin with other anti-diabetic drugs."( Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin.
Andrews, S; Cheatham, B; Dobbins, R; Hanmant, B; Hussey, EK; O'Connor-Semmes, R; Sagar, K; Tao, W; Wilkison, WO, 2021)		0.89
" All subjects were on a stable metformin dosing regimen."( Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin.
Andrews, S; Cheatham, B; Dobbins, R; Hanmant, B; Hussey, EK; O'Connor-Semmes, R; Sagar, K; Tao, W; Wilkison, WO, 2021)		0.89
" Application of the method for assay of drugs in their combined pharmaceutical dosage forms."( Chemometric-Based AQbD and Green Chemistry Approaches to Chromatographic Analysis of Remogliflozin Etabonate and Vildagliptin.
Ahir, H; Prajapati, B; Prajapati, P; Shah, S, 2022)		0.95
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
glycosideA glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium/glucose cotransporter 1Homo sapiens (human)IC50 (µMol)100.00000.06071.61058.4440AID1719619; AID1874422
Sodium/glucose cotransporter 2Homo sapiens (human)IC50 (µMol)2.53000.00050.16534.1000AID1719618; AID1874423
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
chloride transmembrane transportSodium/glucose cotransporter 1Homo sapiens (human)
glucose transmembrane transportSodium/glucose cotransporter 1Homo sapiens (human)
alpha-glucoside transportSodium/glucose cotransporter 1Homo sapiens (human)
intestinal D-glucose absorptionSodium/glucose cotransporter 1Homo sapiens (human)
response to inorganic substanceSodium/glucose cotransporter 1Homo sapiens (human)
pentose transmembrane transportSodium/glucose cotransporter 1Homo sapiens (human)
fucose transmembrane transportSodium/glucose cotransporter 1Homo sapiens (human)
galactose transmembrane transportSodium/glucose cotransporter 1Homo sapiens (human)
myo-inositol transportSodium/glucose cotransporter 1Homo sapiens (human)
transepithelial water transportSodium/glucose cotransporter 1Homo sapiens (human)
renal glucose absorptionSodium/glucose cotransporter 1Homo sapiens (human)
glucose import across plasma membraneSodium/glucose cotransporter 1Homo sapiens (human)
sodium ion import across plasma membraneSodium/glucose cotransporter 1Homo sapiens (human)
intestinal hexose absorptionSodium/glucose cotransporter 1Homo sapiens (human)
transport across blood-brain barrierSodium/glucose cotransporter 1Homo sapiens (human)
glucose transmembrane transportSodium/glucose cotransporter 1Homo sapiens (human)
sodium ion transportSodium/glucose cotransporter 1Homo sapiens (human)
alpha-glucoside transportSodium/glucose cotransporter 2Homo sapiens (human)
carbohydrate metabolic processSodium/glucose cotransporter 2Homo sapiens (human)
hexose transmembrane transportSodium/glucose cotransporter 2Homo sapiens (human)
renal glucose absorptionSodium/glucose cotransporter 2Homo sapiens (human)
glucose import across plasma membraneSodium/glucose cotransporter 2Homo sapiens (human)
sodium ion import across plasma membraneSodium/glucose cotransporter 2Homo sapiens (human)
sodium ion transportSodium/glucose cotransporter 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
galactose transmembrane transporter activitySodium/glucose cotransporter 1Homo sapiens (human)
glucose transmembrane transporter activitySodium/glucose cotransporter 1Homo sapiens (human)
myo-inositol:sodium symporter activitySodium/glucose cotransporter 1Homo sapiens (human)
water transmembrane transporter activitySodium/glucose cotransporter 1Homo sapiens (human)
glucose:sodium symporter activitySodium/glucose cotransporter 1Homo sapiens (human)
protein bindingSodium/glucose cotransporter 1Homo sapiens (human)
pentose transmembrane transporter activitySodium/glucose cotransporter 1Homo sapiens (human)
fucose transmembrane transporter activitySodium/glucose cotransporter 1Homo sapiens (human)
alpha-glucoside transmembrane transporter activitySodium/glucose cotransporter 1Homo sapiens (human)
galactose:sodium symporter activitySodium/glucose cotransporter 1Homo sapiens (human)
D-glucose transmembrane transporter activitySodium/glucose cotransporter 1Homo sapiens (human)
low-affinity glucose:sodium symporter activitySodium/glucose cotransporter 2Homo sapiens (human)
glucose:sodium symporter activitySodium/glucose cotransporter 2Homo sapiens (human)
protein bindingSodium/glucose cotransporter 2Homo sapiens (human)
alpha-glucoside transmembrane transporter activitySodium/glucose cotransporter 2Homo sapiens (human)
D-glucose transmembrane transporter activitySodium/glucose cotransporter 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
early endosomeSodium/glucose cotransporter 1Homo sapiens (human)
plasma membraneSodium/glucose cotransporter 1Homo sapiens (human)
apical plasma membraneSodium/glucose cotransporter 1Homo sapiens (human)
brush border membraneSodium/glucose cotransporter 1Homo sapiens (human)
intracellular organelleSodium/glucose cotransporter 1Homo sapiens (human)
perinuclear region of cytoplasmSodium/glucose cotransporter 1Homo sapiens (human)
extracellular exosomeSodium/glucose cotransporter 1Homo sapiens (human)
intracellular vesicleSodium/glucose cotransporter 1Homo sapiens (human)
plasma membraneSodium/glucose cotransporter 1Homo sapiens (human)
plasma membraneSodium/glucose cotransporter 2Homo sapiens (human)
membraneSodium/glucose cotransporter 2Homo sapiens (human)
apical plasma membraneSodium/glucose cotransporter 2Homo sapiens (human)
extracellular exosomeSodium/glucose cotransporter 2Homo sapiens (human)
plasma membraneSodium/glucose cotransporter 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID418704Antidiabetic activity in normal Sprague-Dawley rat assessed as urinary glucose excretion at 1 mg/kg, po after 24 hrs2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
AID1719618Inhibition of human SGLT2 expressed in COS7 cells assessed as reduction in [14C]-AMG uptake2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor.
AID1874422Inhibition of human SGLT1 expressed in COS-7 cells2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives.
AID1719619Inhibition of human SGLT1 expressed in COS7 cells assessed as reduction in [14C]-AMG uptake2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor.
AID1719628Oral bioavailability in rat assessed as ratio of AUC at 3 mg/kg up to 360 mins by LC-MS/MS analysis2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor.
AID1719623Apparent permeability of compound in human Caco-2 cells by LC-MS/MS analysis2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor.
AID418945Antidiabetic activity in normal Sprague-Dawley rat assessed as urinary glucose excretion at 10 mg/kg, po after 24 hrs2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
AID418944Antidiabetic activity in normal Sprague-Dawley rat assessed as urinary glucose excretion at 3 mg/kg, po after 24 hrs2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
AID1874423Inhibition of human SGLT2 expressed in COS-7 cells2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives.
AID1719621Intrinsic clearance in mouse intestinal S9 fraction at 10 uM up to 60 min in presence of NADPH by LC-MS/MS analysis2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (7.69)29.6817
2010's14 (53.85)24.3611
2020's10 (38.46)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 55.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index55.91 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index5.59 (4.65)
Search Engine Demand Index85.80 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (55.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (46.15%)5.53%
Reviews8 (30.77%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (23.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Evaluation of the Safety, Tolerability, and Pharmacodynamic Effects of GSK189075 When Administered With Furosemide or Hydrochlorothiazide [NCT00671424]Phase 148 participants (Anticipated)Interventional2008-03-31Completed
A 12-week Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Determine the Efficacy and Safety of Biphasic Remogliflozin Etabonate When Administered to Subjects With Type 2 Diabetes Mellitus [NCT02537470]Phase 2191 participants (Actual)Interventional2015-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
lactic acid
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.		4.62112-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
glimepiride
glimepiride: structure given in first source		3.1410sulfonamide
ketoconazole
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.		8.4611dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
metformin
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.		7.8443guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
pioglitazone
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.		5.8522aromatic ether;
pyridines;
thiazolidinediones		antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic
phlorhizin
[no description available]		3.1410aryl beta-D-glucoside;
dihydrochalcones;
monosaccharide derivative		antioxidant;
plant metabolite
fluorine
Fluorine: A nonmetallic, diatomic gas that is a trace element and member of the halogen family. It is used in dentistry as fluoride (FLUORIDES) to prevent dental caries.		2.1710diatomic fluorine;
gas molecular entity		NMR chemical shift reference compound
glucose, (beta-d)-isomer
beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.		13.052212D-glucopyranoseepitope;
mouse metabolite
repaglinide
[no description available]		3.1410piperidines
rosiglitazone
[no description available]		3.1410aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
acarbose
[no description available]		3.1410amino cyclitol;
glycoside
sitagliptin
sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.		3.1410triazolopyrazine;
trifluorobenzene		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
environmental contaminant;
hypoglycemic agent;
serine proteinase inhibitor;
xenobiotic
vildagliptin
[no description available]		4.7241amino acid amide
sergliflozin etabonate
sergliflozin: a hypoglycemic agent that inhibits SGLT2 sodium-glucose transporter; structure in first source		4.7730glycoside
dapagliflozin
[no description available]		4.3830aromatic ether;
C-glycosyl compound;
monochlorobenzenes		hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor
linagliptin
Linagliptin: A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS.. linagliptin : A xanthine that is 7H-xanthine bearing (4-methylquinazolin-2-yl)methyl, methyl, but-2-yn-1-yl and 3-aminopiperidin-1-yl substituents at positions 1, 3, 7 and 8 respectively (the R-enantiomer). Used for treatment of type II diabetes.		3.811aminopiperidine;
quinazolines		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
exenatide
[no description available]		3.1410
pf 04971729
ertugliflozin: structure in first source		3.2510diarylmethane
ConditionIndicatedRelationship StrengthStudiesTrials
Diabetes Mellitus, Adult-Onset
[description not available]		012.26178
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		114.26178
Glycosuria
The appearance of an abnormally large amount of GLUCOSE in the urine, such as more than 500 mg/day in adults. It can be due to HYPERGLYCEMIA or genetic defects in renal reabsorption (RENAL GLYCOSURIA).		05.8842
Hyperglycemia, Postprandial
Abnormally high BLOOD GLUCOSE level after a meal.		07.8242
Hyperglycemia
Abnormally high BLOOD GLUCOSE level.		07.8242
Cytomegalic Inclusion Disease
[description not available]		02.4110
Cytomegalovirus Infections
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.		02.4110
Dizzyness
[description not available]		04.3911
Bilateral Headache
[description not available]		04.3911
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		04.3911
Dizziness
An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.		04.3911
Electrolytes
Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed)		04.3911
Headache
The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.		04.3911
Fasting Hypoglycemia
HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.		04.4111
Weight Reduction
[description not available]		05.8522
Hypoglycemia
A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH.		04.4111
Hypertriglyceridemia
A condition of elevated levels of TRIGLYCERIDES in the blood.		04.4111
Weight Loss
Decrease in existing BODY WEIGHT.		05.8522
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		03.511
Autoimmune Diabetes
[description not available]		05.7121
Diabetes Mellitus, Type 1
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.		17.7121
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0410
Insulin Sensitivity
[description not available]		02.0410
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.		02.0410
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		03.4611